Type 1 Diabetes

Once-daily oral verapamil may help preserve stimulated C-peptide secretion for children and adolescents with type 1 diabetes, according to a study published in JAMA.

Advanced hybrid closed-loop therapy reduces HbA1c and improves time in range among adolescents and young adults with type 1 diabetes, with few serious adverse events, according to findings published in Diabetes Care.

Children who develop type 1 diabetes may have biomarkers present in the gut microbiome as early as age 1 year, according to a study published in Diabetologia.

Hepatic steatosis may be present in most adults with type 1 diabetes, especially those with overweight or obesity, according to a study published in Journal of Diabetes and Its Complications.

Young children using a hybrid closed-loop insulin delivery system had a greater time in range at 13 weeks compared with those receiving standard care, according to a study published in The New England Journal of Medicine.

Adults with type 1 diabetes using insulin glargine had comparable continuous glucose monitoring metrics at 12 weeks as those who used insulin degludec, according to a presenter.

Most adults with type 1 or type 2 diabetes in the United States reported experiencing social stigma, and many also reported that social stigma impacted their decision to not use an insulin pump or continuous glucose monitoring device, data show.

Adults with type 1 diabetes spent more time in range with empagliflozin 2.5 mg or 5 mg as an adjunctive therapy to hybrid closed-loop insulin therapy compared with placebo, according to a speaker.

Once-daily liraglutide 3 mg as an adjunctive to lifestyle intervention is associated with a reduction in body weight and HbA1c for adolescents with type 1 diabetes and obesity, according to a speaker.

Children with type 1 diabetes who switched from a predictive low-glucose suspend system to automated insulin delivery had improvements in time in range at 1 month that were sustained at 3 months, according to a speaker.